Literature DB >> 32417305

The importance of a centralized line service during the COVID-19 pandemic.

Nicole Ilonzo1, Ajit Rao2, Krish Soundararajan2, Ageliki Vouyouka2, Daniel Han2, Rami Tadros2, Sung Yup Kim2, Barry Love2, Windsor Ting2, Michael Marin2, Peter Faries2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32417305      PMCID: PMC7224659          DOI: 10.1016/j.jvs.2020.05.016

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


× No keyword cloud information.
As vascular surgeons in New York City, we are currently in the epicenter of the COVID-19 crisis in the United States. As of April 24, 2020, there are 869,172 COVID-19 cases in the United States, of which >600,000 are in New York City. Mount Sinai Health System has one of the largest consortiums of COVID-19 patients in New York City. To meet the demand of the increasing numbers of hospitalized patients with COVID-19, many health care providers have been placed in roles outside of their immediate level of training and are often treating a large cohort of patients. In part, this has resulted in a sharp increase in the rate of central line complications, resulting in urgent vascular surgery consultation and intervention. The cause of complications after central line insertion is likely to be multifactorial. Ultrasound-guided access has been shown to decrease central line complications. , Emergent line insertion and placement by an inexperienced practitioner also increase central line complications. Intensive care units are at full capacity with critically ill COVID-19 patients. These errors after central line insertions will also result in increased exposure of frontline health care workers to the virus from the workup, imaging, and intervention needed to manage these complications. In response to this, we have created line service teams to assist with central and arterial line placements throughout the Mount Sinai Health system. However, the COVID-19 pandemic brings important challenges and considerations to central line placements that are patient and institution specific and will alter treatment algorithms. We discuss some of these considerations.

Structure of line service

The composition of the line service team should be tailored to the specific institution according to availability of staff and volume of access consultations. In our health system, our line service teams consist of multiple vascular surgeons, interventional radiologists, and interventional cardiologists who have extensive experience in ultrasound-guided vascular access. Although composition of the team varies between hospital, each shift generally has at least two attending physicians and one or two ancillary staff. Each shift is 8 to 12 hours, and the line service is available at least 5 days a week. There are approximately 5 to 10 requests for line insertions per day per hospital. To date, all cases have been performed at bedside, but a negative pressure room in a fluoroscopy suite is available for difficult line insertions. The attending physician performs the procedure and the ancillary staff is in the patient's room to assist with line placement. Under ultrasound guidance, the central line is inserted in the usual fashion and secured with silk suture. Each port is instilled with heparinized saline (5000 units/mL), and a biopatch and sterile dressing are applied.

Selection of patients

Although data are limited, there appears to be an alarmingly high mortality rate in critically ill patients with COVID-19 infection. Thus, it is important to consider the prognosis of a patient before placing a central line. Futile line insertions will subject the staff to unnecessary viral exposure as well as misallocation of limited medical supplies and personal protective equipment. In particular, a significant portion of patients with severe COVID-19 disease will develop renal failure requiring hemodialysis, and the prognosis appears to be poor. This is limiting available hemodialysis machines and exposing the dialysis staff to COVID-19. Thus, it is particularly important in these patients needing hemodialysis access that a goals of care discussion be held before line insertion whenever possible. In nonintubated patients who are hemodynamically stable, preference can be given to placement of midline catheters or large-bore peripheral intravenous access.

Available hospital resources

The line team has one disposable premade bag for each central line that contains all equipment needed, including personal protective equipment, ultrasound probe cover, and central line kit. The ultrasound machines are meticulously cleaned with an alcohol-based solution after every use. We realize that some institutions may have limited access to ultrasound machines, in which case anatomic landmarks can be used. This will also avoid transporting and cleaning an ultrasound machine for each procedure. In addition, portable chest radiographs may be difficult to obtain in a timely fashion during the COVID-19 crisis. An advantage of femoral vein access is that no postprocedure chest radiograph is needed. However, for straightforward internal jugular vein central lines, postprocedure chest radiographs are not routinely ordered to avoid potential exposure of radiology staff to the virus.

Location of central line

The internal jugular or subclavian vein is generally used for access because of potentially lower rates of infection. , However, in patients who are at high risk for aerosolizing the infection (nonintubated patients on high-flow nasal cannula or bilevel positive airway pressure) or patients who are unable to lie flat, the femoral vein is preferentially chosen for line placement. The majority of these high-risk for aerosolization procedures have been in nonintubated patients with COVID-19 and renal failure requiring hemodialysis access. In addition, a significant portion of patients with severe COVID-19 may require prone positioning to improve oxygenation and ventilation. In these instances, femoral lines will be much more difficult to access, and preference can be given to internal jugular vein access. Some providers have routinely placed triple-lumen catheters in the left internal jugular or subclavian vein, so the right side can be used for hemodialysis catheters if needed. An alternative is that both the triple-lumen catheter and dialysis catheter can be placed on the right side, with spacing of the access sites in the neck. We have noted that many of our lines have thrombosed shortly after line insertion when instilled with saline or low-dose heparin. Thus, we have begun to instill each port of the central line with heparinized saline (5000 units/mL).

Final thoughts

The COVID-19 pandemic has resulted in a large volume of central line insertions and an urgent need for an experienced team to facilitate line placement. Vascular surgeons and interventionalists can serve an urgent and important role by creating a central venous access team and tailoring it to the needs of their institution. The authors would like to thank all the physicians, nurses, ancillary staff, and front-line providers in the Mount Sinai Health System who organized and participated in the central line teams during the COVID-19 pandemic.
  6 in total

1.  Special article: retained guidewires after intraoperative placement of central venous catheters.

Authors:  Andrea Vannucci; Alicia Jeffcoat; Catherine Ifune; Christian Salinas; James R Duncan; Michael Wall
Journal:  Anesth Analg       Date:  2012-06-05       Impact factor: 5.108

2.  COVID-19 and the Inpatient Dialysis Unit: Managing Resources during Contingency Planning Pre-Crisis.

Authors:  Anna Burgner; T Alp Ikizler; Jamie P Dwyer
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-03       Impact factor: 8.237

3.  Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial.

Authors:  J Merrer; B De Jonghe; F Golliot; J Y Lefrant; B Raffy; E Barre; J P Rigaud; D Casciani; B Misset; C Bosquet; H Outin; C Brun-Buisson; G Nitenberg
Journal:  JAMA       Date:  2001-08-08       Impact factor: 56.272

4.  Meta-analysis of subclavian insertion and nontunneled central venous catheter-associated infection risk reduction in critically ill adults.

Authors:  Jean-Jacques Parienti; Damien du Cheyron; Jean-François Timsit; Ousmane Traoré; Pierre Kalfon; Olivier Mimoz; Leonard A Mermel
Journal:  Crit Care Med       Date:  2012-05       Impact factor: 7.598

Review 5.  Ultrasound guidance versus anatomical landmarks for internal jugular vein catheterization.

Authors:  Patrick Brass; Martin Hellmich; Laurentius Kolodziej; Guido Schick; Andrew F Smith
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

Review 6.  Ultrasound-guided central venous catheter placement: a structured review and recommendations for clinical practice.

Authors:  Bernd Saugel; Thomas W L Scheeren; Jean-Louis Teboul
Journal:  Crit Care       Date:  2017-08-28       Impact factor: 9.097

  6 in total
  3 in total

1.  Safe Central Venous Access in an Overburdened Health System.

Authors:  Karen Woo; David Rigberg; Peter F Lawrence
Journal:  JAMA       Date:  2021-01-19       Impact factor: 56.272

2.  Balloon-Assisted Percutaneous Thrombin Injection for Treatment of Iatrogenic Left Subclavian Artery Pseudoaneurysm in a Critically Ill COVID-19 Patient.

Authors:  Hassan Al-Thani; Ahmed Hussein; Ahmed Sadek; Ali Barah; Ayman El-Menyar
Journal:  Case Rep Vasc Med       Date:  2021-10-07

3.  Managing central venous access during a health care crisis.

Authors:  Tristen T Chun; Dejah R Judelson; David Rigberg; Peter F Lawrence; Robert Cuff; Sherene Shalhub; Max Wohlauer; Christopher J Abularrage; Papapetrou Anastasios; Shipra Arya; Bernadette Aulivola; Melissa Baldwin; Donald Baril; Carlos F Bechara; William E Beckerman; Christian-Alexander Behrendt; Filippo Benedetto; Lisa F Bennett; Kristofer M Charlton-Ouw; Amit Chawla; Matthew C Chia; Sungsin Cho; Andrew M T L Choong; Elizabeth L Chou; Anastasiadou Christiana; Raphael Coscas; Giovanni De Caridi; Sharif Ellozy; Yana Etkin; Peter Faries; Adrian T Fung; Andrew Gonzalez; Claire L Griffin; London Guidry; Nalaka Gunawansa; Gary Gwertzman; Daniel K Han; Caitlin W Hicks; Carlos A Hinojosa; York Hsiang; Nicole Ilonzo; Lalithapriya Jayakumar; Jin Hyun Joh; Adam P Johnson; Loay S Kabbani; Melissa R Keller; Manar Khashram; Issam Koleilat; Bernard Krueger; Akshay Kumar; Cheong Jun Lee; Alice Lee; Mark M Levy; C Taylor Lewis; Benjamin Lind; Gabriel Lopez-Pena; Jahan Mohebali; Robert G Molnar; Nicholas J Morrissey; Raghu L Motaganahalli; Nicolas J Mouawad; Daniel H Newton; Jun Jie Ng; Leigh Ann O'Banion; John Phair; Zoran Rancic; Ajit Rao; Hunter M Ray; Aksim G Rivera; Limael Rodriguez; Clifford M Sales; Garrett Salzman; Mark Sarfati; Ajay Savlania; Andres Schanzer; Mel J Sharafuddin; Malachi Sheahan; Sammy Siada; Jeffrey J Siracuse; Brigitte K Smith; Matthew Smith; Ina Soh; Rebecca Sorber; Varuna Sundaram; Scott Sundick; Tadaki M Tomita; Bradley Trinidad; Shirling Tsai; Ageliki G Vouyouka; Gregory G Westin; Michael S Williams; Sherry M Wren; Jane K Yang; Jeniann Yi; Wei Zhou; Saqib Zia; Karen Woo
Journal:  J Vasc Surg       Date:  2020-07-15       Impact factor: 4.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.